Treatment Options for Alopecia Areata in Children and Adolescents

Paediatr Drugs. 2024 May;26(3):245-257. doi: 10.1007/s40272-024-00620-2. Epub 2024 Mar 11.

Abstract

Alopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with pediatric patients were included in this review. Commonly used therapies, including corticosteroids, methotrexate, and minoxidil, newer promising medications, such as Janus kinase inhibitors, and less frequently used topical and systemic treatments are included. A summary of the drug development pipeline and ongoing interventional clinical trials with pediatric patients is provided. Treatments demonstrate variable efficacy, and many patients require combination therapy for maximal response. More robust clinical data is needed for many of the medications reviewed in order to provide better care for these patients.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / therapeutic use
  • Alopecia Areata* / drug therapy
  • Alopecia Areata* / therapy
  • Child
  • Humans
  • Janus Kinase Inhibitors / therapeutic use
  • Minoxidil / administration & dosage
  • Minoxidil / therapeutic use

Substances

  • Minoxidil
  • Adrenal Cortex Hormones
  • Janus Kinase Inhibitors